TPTatyana A. Prokhorova

Tatyana A. Prokhorova

*This is an algorithmically generated author record based on publicly available information.

Tatyana A. Prokhorova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The association between blood enzyme activity in patients with depression and delusional disorders and their response to psychopharmacotherapy

    by O.K. Savushkina, S.V. Sizov, I.V. Oleichik, P.A. Baranov, I.S. Boksha, T.A. Prokhorova, E.B. Tereshkina, E.A. Vorobyeva, G.SH. Burbaeva, E.V. Semina, et al.

    Objective. To identify biochemical parameters correlated with the characteristics of the clinical response to psychopharmacotherapy (PFT) in patients with depressive-delusional states of various nosological origins. Material and methods. This study included 54 patients, aged 18 to 52 years, diagnosed with depression and delusional disorders across various nosological categories (F20.02; F25.1; F31.5 according to ICD-10). Scores were obtained using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HAM-D), both administered before and after PPT. Prior to initiating treatment, the activity of enzymes involved in energy metabolism, glutamate metabolism, and antioxidant/glutathione metabolism in platelets and red blood cells was measured. Results. The patient population was segmented into two distinct diagnostic subgroups: schizophrenia spectrum disorders (SSD; F20.02; F25.1; n=34) and affective spectrum disorders (F31.5; n=21). Biochemical parameters were identified within these subgroups that correlated with reductions in PANSS (redPANSS) and HAM-D scores, as well as with scores on these scales following completion of the PPT (PANSS2). In the subgroup with affective disorders, significant correlations were observed between creatine phosphokinase (CPK) activity and redPANSS-Neg (R=0.47, p=0.02), as well as with PANSS-Neg2 (R=–0.52, p=0.01); glutamate dehydrogenase activity also correlated with PANSS-Pos2 (R=–0.48, p=0.01). In the SSD subgroup, correlations were found between CPK and glutathione S-transferase (GST) activity and redPANSS-Pos (R=0.38 and R=0.44, p<0.03). Furthermore, within two distinct patient clusters (n=29 and n=26) identified by biochemical characteristics, notable correlations were observed: in the larger cluster, the CPK activity correlated with redPANSS-Tot, redPANSS-Pos, redPANSS-Neg, and PANSS-Tot2 (R=0.47, R=0.53, R=0.43, R=–0.47, p<0.02); in the smaller cluster, a correlation was identified between the red blood cell GST activity and redPANSS-Neg (R=0.46, p=0.02). Conclusion. The identified significant correlations between biochemical parameters and the degree of reduction in the total score on psychometric scales after the course of therapy make it possible to use these potential candidates as biomarkers in clinical practice to predict the effectiveness of PFT.

  • Measurement of platelet enzymatic activities in assessing the clinical response to antipsychotic therapy in patients with late-onset schizophrenia-like psychoses

    by O.K. Savushkina, I.S. Boksha, V.V. Pochueva, T.A. Prokhorova, E.B. Tereshkina, V.S. Sheshenin, E.A. Vorobyeva, G.SH. Burbaeva

    Objective. To identify correlations between the levels of platelet enzyme activity and clinical responses to antipsychotic pharmacotherapy in patients diagnosed with late-onset manifesting schizophrenia-like psychosis (late-onset schizophrenia, LOS) and very late-onset manifesting schizophrenia-like psychosis (VLOSLP). Material and methods. The mental health status of 76 hospitalized patients with LOS and VLOSLP was evaluated using standardized psychometric scales at two time points: prior to the initiation of treatment and after a 28-day course of psychotropic therapy. Prior to treatment commencement, the activity levels of platelet enzymes involved in glutamate metabolism, energy metabolism, and glutathione antioxidant metabolism were measured for all subjects. A statistical analysis of the database with clinical and biochemical examination results, was conducted. Results. A comprehensive psychopathological assessment enabled the identification of patients exhibiting specific small-range delusions within their psychosis, notably «dwelling paranoid» delusions. It was observed that this type of delirium was predominantly present in patients with VLOSLP (X²=9.8, p=0.0018 with Yates correction). When participants were categorized into subgroups based on the presence or absence of «dwelling paranoid» delusions, a significant difference in platelet glutamate dehydrogenase activity was noted: patients exhibiting this type of delirium demonstrated significantly higher activity levels (p=0.009). Furthermore, several notable clinical and biological correlations were established between platelet enzyme activity levels and the clinical response to psychotropic therapy. Conclusions. The significant correlations identified between platelet enzyme activity levels prior to therapy and individual clinical responses to psychotropic interventions hold potential for prognostic applications in clinical psychiatry, particularly for patients with disorders along the schizophrenia spectrum in later life.

  • Open Access

    Creatine – Creatine Phosphate System in Healthy Persons and in Patients with Mental Disorders

    by G. Sh. Burbaeva, I. S. Boksha, O. K. Savushkina, T. A. Prokhorova, E. B. Tereshkina, E. A. Vorobyeva

    Background: the normal brain functioning is provided by a brain system maintaining pools and balance of concentrations of the main high-energy compounds, such as ATP and creatine phosphate (CrP), with its main components — creatine (Cr), creatine phosphate (CrP) and creatine phosphokinase (or creatine kinase, CK), the last is catalyzing the reaction of high-energy phosphate residue transfer between ATP, Cr and CrP. The purpose of this review is to analyze the results of studies on the elements of the Cr — CrP system: Cr, CrP and CK in healthy persons and in patients with mental and neurodegenerative disorders and to consider the possibilities of using Cr — CrP-targeted therapy for mental and neurodegenerative disorders. Methods: using combinations of keywords “creatine”, “creatine phosphate”, “creatine kinase”, “schizophrenia”, “bipolar affective disorder”, “Alzheimer’s disease” and “pharmacotherapy”, a search was conducted for sources in the Medline/PubMed, Scopus and RSCI databases. Conclusion: a critical examination of the original articles, both clinical and experimental, including studies performed on animal models, provides a good reason to believe that the involvement of the Cr — CrP system in the pathogenesis of mental illnesses has been confirmed and opens up further prospectives for Cr — CrP-oriented therapy of mental and neurodegenerative disorders, however, further clinical studies of the Cr — CrP system in psychiatry are necessary.


  • Open Access

    Activity of Platelet and Erythrocyte Enzymes of Glutathione Metabolism in Patients with Schizophrenia Spectrum Disorders with Periodic Catatonia

    by O. K. Savushkina, I. S. Boksha, T. A. Prokhorova, E. B. Tereshkina, E. A. Vorobyeva, M. V. Piskarev, G. Sh. Burbaeva

    Background: oxidative stress and glutathione antioxidant system are pathogenetic chains involved both in the pathogenesis of schizophrenia and schizophrenia spectrum disorders (SSD), and in the development of catatonia, which is often found in schizophrenia and SSD. The aim: is to stratify patients with periodic catatonia in schizophrenia and SSD, based on the activity of platelet and erythrocyte enzymes of glutathione system and to comparatively analyze the activity of the enzymes in patients with different forms of catatonia. Patients and Methods: patients with schizophrenia and SSD with hypo-; para- and multi-kinetic forms of periodic catatonia (n = 13, 11 and 15, respectively) and mentally healthy persons of control group (n = 21) were included into the study. Activities of glutathione reductase and glutathione-S-transferase were determined by spectrophotometric kinetic methods in extracts of platelets and erythrocytes from the blood of patients and the control group. Results: when clustering patients by these four biochemical characteristics, two clusters were obtained with the enzymatic activities significantly differed from the levels in the control group, and significantly uneven distribution of patients with different forms of catatonia was observed between the clusters: χ2 = 20.3, p < 0.0001 (with Yates’ correction) for patients with hypo- and para-kinetic catatonia; χ2 = 16.9, p < 0.0001 (with Yates’ correction) for patients with para- and multi-kinetic catatonia. Conclusions: patients with different forms of catatonia are characterized by different patterns of changes in the activity levels of the studied enzymes relatively to the control ranges. Determining the activity of glutathione enzymes in the blood of patients with SSD is informative for in-depth stratification of such patients, including in differentiating the forms of catatonia in SSD, and these biochemical parameters can serve as an addition to clinical characteristics to clarify the form of periodic catatonia.

  • Proinflammatory activity of monocytes and activity of glutathione-dependent enzymes in red blood cells in women with depressive conditions

    by E.F. Vasilyeva, O.K. Savushkina, T.A. Prokhorova, E.B. Tereshkina, I.S. Boksha, S.V. Sizov, I.V. Oleichik

    Objective. To search for possible connections between the anti-inflammatory activity of monocytes (PAM) and the activity of glutathione metabolic enzymes: glutathione reductase (GR) and glutathione-S-transferase (GT) in patients with depressive states (DS) within various mental pathologies, as well as between the studied biological parameters and clinical condition of patients. Material and methods. Sixty-one women, aged 18—56 years, with DC were examined before and after treatment. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depressive Symptom Rating Scale (HDRS-21). The control group included 23 women of the corresponding age without mental pathology. Biological parameters were assessed in the peripheral blood of patients and healthy people. Results. Patients with a high level of PAM compared to the control (p<0.001) (subgroup 1, n=31) and with a low (at the control level) level (subgroup 2, n=30) were identified. In the subgroup 1, the values of GR and GT were significantly lower than in patients of subgroup 2 (p<0.05 and p<0.01, respectively). Negative correlations between the level of PAM before treatment and GR before and after treatment were revealed in patients who responded to treatment (r=–0.67; p=0.0041; r=–0.76; p=0.0001). Conclusion. The results may indicate the inverse relationship between the level of PAM and the activity of GR and GT, which are involved in the pathogenesis of DC, and can also serve as criteria for assessing the response of patients to treatment.


  • Clinical and psychopathological characteristics of patients with late-onset schizophrenia and schizophrenia-like psychoses in clusters identified by biological parameters

    by T.A. Prokhorova, L.V. Androsova, E.B. Tereshkina, I.S. Boksha, O.K. Savushkina, V.V. Pochueva, V.S. Sheshenin, G.SH. Burbaeva, T.P. Klyushnik

    OBJECTIVE To assess clinical and psychopathological characteristics of late-aged female patients with late-onset psychoses in clusters formed on the basis of biochemical and immunological blood parameters. MATERIAL AND METHODS We examined 59 women with schizophrenia and schizophrenia-like psychoses with onset after 40 years (ICD-10 F20, F22.8, F25, F23, F06.2), including 34 women with late-onset (40—60 years) and 25 with very late onset psychoses (after 60 years). At the time of hospitalization, a clinical/ psychopathological study was carried out using CGI-S, PANSS, CDSS, and HAMD-17, as well as the activities of glutathione reductase (GR) and glutathione-S-transferase (GT) have been determined in erythrocyte hemolysates, and the activities of leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) have been assessed in blood plasma. Biochemical and immunological parameters have been also determined in 34 age-matched mentally healthy women. RESULTS Clustering by signs such as GR, GT, LE and α1-PI has yielded two clusters of objects (patients) significantly different in GT (pppp=0.04) and higher total scores on PANSS subscales’ items. Cluster 1 includes 76% of patients with very late onset. Different correlations between clinical and biological signs are found in two clusters. CONCLUSION The identified clusters have different clinical and psychopathological characteristics. Dividing patients into subgroups according to biochemical and immunological parameters is promising for the search for differentiated therapeutic approaches.


  • Open Access

    Multifactorial, biomarker-based model for assessing the state of patients with schizophrenia

    by E. G. Cheremnykh, O. K. Savushkina, T. A. Prokhorova, S. A. Zozulya, I. N. Otman, A. N. Pozdnyakova, N. S. Karpova, Yu. E. Shilov, T. P. Klyushnik

    Relevance. Objective comparison of biological markers and real clinical presentation is especially difficult in mental disorders, which are classified according to a large number of diagnostic criteria and a wide variety of symptoms. Therefore, the development of an effective system of biochemical markers and assessment of their relationship to optimize the diagnosis and treatment of schizophrenia are relevant.The aim of the study was to develop a statistical model that combines known and tested biochemical markers for mental illnesses in patients with schizophrenia.Materials and methods. The study included 47 women aged 18–50 years (median age – 22 years) with the diagnosis of schizophrenia (ICD-10, F20) and 25 healthy women of the same age. The model was based on the functional activity of complement, thrombodynamics parameters, markers of inflammation, glutamate and energy metabolism, and antioxidant defense, which were shown to be associated with the severity of schizophrenia. The listed markers were evaluated in plasma, platelets, and erythrocytes of sick and healthy individuals.Results. Statistical software found pair correlations and features of the distribution of all markers as random variables in the examined groups and evaluated correlations between pairs of markers. Ten biomarkers were identified and united into a system that was adequately described by the logistic regression model. The model was evaluated using the Pearson’s test (χ2(11) = 57.6, p = 0.001) and calculation of correct predictions (91 and 80%) for samples of patients and healthy people, respectively.Conclusion. Calculating the logistic equation resulted in the probability that the patient has schizophrenia involving the immune system, hemostasis, and oxidative stress. This model can be considered as a new formalized approach to the preclinical diagnosis of mental illnesses.


  • Open Access

    Oxidative Stress in Schizophrenia: Relation to Neurochemical Pathogenetic Hypotheses

    by G. Sh. Burbaeva, T. A. Prokhorova, O. K. Savushkina, E. B. Tereshkina, E. A. Vorobyeva, I. S. Boksha

       Background: heterogeneity of schizophrenia is reflected in the variety of clinical manifestations and biological disorders, on the basis of which several neurochemical hypotheses are formulated for schizophrenia pathogenesis. Review of the current hypotheses of schizophrenia pathogenesis shows that oxidative stress is not the main cause of the disease development, but affects its course and contributes to the deterioration of the patient’s condition.   Objective: analysis of the relationships between redox imbalance and oxidative stress and the development of pathological processes in schizophrenia within the framework of neurochemical hypotheses of the disease pathogenesis.   Material and methods: a search was made for sources in the Medline/PubMed databases, Scopus and RSCI using keyword combinations “oxidative stress”, “oxidation-reduction imbalance”, “schizophrenia”, “hypotheses of schizophrenia pathogenesis”, “antioxidants”, “neurotransmitters”, “glutathione”, “neuroinflammation”.   Conclusion: data from numerous studies of the brain of patients with schizophrenia, their blood plasma, serum, and blood cells as well as the study of animal models of schizophrenia indicate the presence of redox imbalance and oxidative stress in this disease. Taken together, these data indicate that genetic and environmental factors that affect the manifestation of various pathological mechanisms in schizophrenia (disturbances in neurotransmitter systems, hypofunction of N-methyl-D-aspartate receptors, neuroinflammation, impaired signaling protein phosphorylation pathways) lead to the oxidative stress, enhancing the initial pathological changes, as a result of which synchronization processes and intercellular communications in the brain become disrupted. Medicines with antioxidant and anti-inflammatory properties, compounds for correcting mitochondrial dysfunction, and NMDAR-mediated signaling modulators can be used as drugs to reduce the harmful effects of oxidative stress. The efficacy of these medicines may vary in different patients, so the development of biomarker systems aimed at identifying individuals who are more likely to respond to a particular drug is of great importance.